Breaking News

Kemwell Appoints President

By Kristin Brooks | March 24, 2014

Advant brings 20 years of industry experience

Siddharth J. Advant, Ph.D. has been appointed president of biopharmaceutical services at Kemwell Biopharma. Anurag Bagaria, chairman and managing director, said, “Dr. Advant exemplifies Kemwell’s commitment to delivering high performance to its customers. He is a proven leader with over 20 years of experience in the biopharmaceutical industry. His extensive experience in CMC development and commercialization will help Kemwell grow its contract biotech business. As a member of Kemwell’s core committee for strategic growth, Dr. Advant will lead a team of professionals charged with developing and delivering high-quality services in the most efficient manner possible to biopharmaceutical companies globally.”
 
Dr. Advant brings 20 years of industry experience having held a variety of leadership positions across the biopharma industry. He joins the company from ImClone Systems, a subsidiary of Eli Lilly & Co., where he was associate vice president of CMC project management. Prior to ImClone, Dr. Advant was the head of Tunnell Consulting’s West Coast Office. He also served as director for Diosynth Biotechnology, heading project management and business alliances, technology transfer and clinical operations, and pharmaceutical sciences and stability, and worked as a scientist in the pharmaceutical development division at Protein Design Labs, Inc.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016